US20260097110
2026-04-09
Human necessities
A61K39/12
The patent application discusses RNA vaccines targeting betacoronaviruses and other respiratory viruses. These vaccines utilize messenger RNA (mRNA) to instruct the body's cells to produce specific proteins, potentially inducing a balanced immune response. The focus is on developing vaccines that provide both cellular and humoral immunity without the risks associated with DNA vaccines, such as insertional mutagenesis.
Respiratory diseases, including those caused by viruses like hMPV, PIV3, RSV, and MeV, pose significant health challenges globally. Betacoronaviruses, such as MERS-CoV and SARS-CoV, also contribute to respiratory illnesses. Despite ongoing research, effective vaccines for many of these viruses remain elusive, underscoring the need for innovative approaches like RNA vaccines.
RNA vaccines leverage the body's natural cellular machinery to produce proteins that can trigger immune responses. This method offers advantages over traditional vaccines, potentially leading to higher antibody titers and faster immune responses. Unlike ex vivo manufactured vaccines, RNA vaccines present antigens in a more native form, which may reduce unwanted cellular responses.
The vaccines are formulated as RNA polynucleotides within cationic lipid nanoparticles, which enhance delivery and expression of the target antigens. This formulation aims to improve the vaccine's effectiveness against various genotypes and strains of respiratory viruses, including betacoronaviruses, by ensuring proper protein conformation and immune activation.
The application highlights the surprising efficacy boost when mRNA vaccines are combined with a flagellin adjuvant. This combination, involving mRNAs encoding both antigens and flagellin, may enhance the vaccine's immunogenicity, offering a promising strategy for developing more effective respiratory virus vaccines.